• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Barriers and Opportunities for Use of Patient Registries in Medicines Regulation.

作者信息

Olmo Carla Alonso, McGettigan Patricia, Kurz Xavier

机构信息

Pharmacovigilance and Epidemiology Department, European Medicines Agency, Amsterdam, The Netherlands.

William Harvey Research Institute, Queen Mary University of London, London, UK.

出版信息

Clin Pharmacol Ther. 2019 Jul;106(1):39-42. doi: 10.1002/cpt.1414. Epub 2019 Apr 10.

DOI:10.1002/cpt.1414
PMID:30970160
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6617975/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e31/6617975/9142ff7e7c98/CPT-106-39-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e31/6617975/9142ff7e7c98/CPT-106-39-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e31/6617975/9142ff7e7c98/CPT-106-39-g001.jpg

相似文献

1
Barriers and Opportunities for Use of Patient Registries in Medicines Regulation.药品监管中使用患者登记系统的障碍与机遇
Clin Pharmacol Ther. 2019 Jul;106(1):39-42. doi: 10.1002/cpt.1414. Epub 2019 Apr 10.
2
Pharmacovigilance in Europe and North America: divergent approaches.欧洲和北美的药物警戒：不同的方法。
Soc Sci Med. 2012 Jul;75(1):165-70. doi: 10.1016/j.socscimed.2011.11.046. Epub 2012 Apr 3.
3
Estimation of potency of Hepatitis B immunoglobulin marketed in India to evaluate the manufacturer's production consistency: Role of National Control Laboratory.评估印度市场上乙型肝炎免疫球蛋白的效价以评价制造商的生产一致性：国家控制实验室的作用
Biologicals. 2019 May;59:72-73. doi: 10.1016/j.biologicals.2019.03.005. Epub 2019 Mar 25.
4
Health authorities and drug utilization studies.卫生当局与药物利用研究。
WHO Reg Publ Eur Ser. 1993;45:147-67.
5
An underrecognized challenge in evaluating postmarketing drug safety.评估上市后药品安全性方面一个未得到充分认识的挑战。
Circulation. 2005 Jan 25;111(3):246-8. doi: 10.1161/01.CIR.0000154578.45378.8C.
6
A new era in drug regulation?药品监管的新时代？
Hastings Cent Rep. 2005 May-Jun;35(3):10-1.
7
Health Canada's Progressive Licensing Framework.加拿大卫生部的渐进式许可框架。
CMAJ. 2007 Jun 19;176(13):1845-7. doi: 10.1503/cmaj.070597.
8
25 years of the Committee on Safety of Medicines. An international perspective of the benefits.药品安全委员会成立25周年。从国际视角看其益处。
Drug Saf. 1990 May-Jun;5(3):161-7. doi: 10.2165/00002018-199005030-00001.
9
Real-World Data for Regulatory Decision Making: Challenges and Possible Solutions for Europe.用于监管决策的真实世界数据：欧洲面临的挑战与可能的解决方案
Clin Pharmacol Ther. 2019 Jul;106(1):36-39. doi: 10.1002/cpt.1426. Epub 2019 Apr 10.
10
Responsibility for pharmaceutical company samples.
N Z Med J. 2005 May 20;118(1215):U1472.

引用本文的文献

1
Real-World Data Included in Post-authorisation Measures: A Case Study of Approved Advanced Therapy Medicinal Products in the European Union between 2013 and 2024.上市后措施中包含的真实世界数据：2013年至2024年欧盟批准的高级治疗药品案例研究
BioDrugs. 2025 Aug 26. doi: 10.1007/s40259-025-00737-x.
2
COVID-19 vaccine registry for pregnant women: policy to control complications of vaccination in pregnant women in 2021-2022.COVID-19 疫苗接种妊娠登记系统：2021-2022 年针对孕妇接种疫苗并发症控制的政策。
BMC Pregnancy Childbirth. 2023 Jul 27;23(1):542. doi: 10.1186/s12884-023-05856-3.
3
The Metreleptin Effectiveness and Safety Registry (MEASuRE): concept, design and challenges.

本文引用的文献

1
Registries supporting new drug applications.支持新药申请的注册。
Pharmacoepidemiol Drug Saf. 2017 Dec;26(12):1451-1457. doi: 10.1002/pds.4332. Epub 2017 Oct 6.
2
Registries in European post-marketing surveillance: a retrospective analysis of centrally approved products, 2005-2013.欧洲上市后监测中的注册研究：2005-2013 年集中批准产品的回顾性分析。
Pharmacoepidemiol Drug Saf. 2017 Dec;26(12):1442-1450. doi: 10.1002/pds.4196. Epub 2017 Mar 26.
Metreleptin 有效性和安全性注册研究（MEASuRE）：概念、设计和挑战。
Orphanet J Rare Dis. 2023 May 26;18(1):127. doi: 10.1186/s13023-023-02714-5.
4
So You Want to Build Your Disease's First Online Patient Registry: An Educational Guide for Patient Organizations Based on US and European Experience.那么，你想要建立你的疾病的首个在线患者登记处：基于美国和欧洲经验的患者组织教育指南。
Patient. 2023 May;16(3):183-199. doi: 10.1007/s40271-023-00619-w. Epub 2023 Mar 22.
5
Contribution of patient registries to regulatory decision making on rare diseases medicinal products in Europe.患者登记系统对欧洲罕见病药品监管决策的贡献。
Front Pharmacol. 2022 Aug 4;13:924648. doi: 10.3389/fphar.2022.924648. eCollection 2022.
6
Collection of Data on Adverse Events Related to Medicinal Products: A Survey Among Registries in the ENCePP Resources Database.药物不良反应数据收集：ENCEPP 资源数据库中注册机构的调查。
Drug Saf. 2022 Jul;45(7):747-754. doi: 10.1007/s40264-022-01188-x. Epub 2022 Jun 21.
7
Editorial: Registries and Population Databases in Clinical Research and Practice.社论：临床研究和实践中的注册研究和人口数据库。
Med Sci Monit. 2021 Jun 14;27:e933554. doi: 10.12659/MSM.933554.
8
Using digital technologies in clinical trials: Current and future applications.在临床试验中使用数字技术：当前和未来的应用。
Contemp Clin Trials. 2021 Jan;100:106219. doi: 10.1016/j.cct.2020.106219. Epub 2020 Nov 17.
9
Inhibitor development in previously untreated patients with severe haemophilia: A comparison of included patients and outcomes between a clinical study and a registry-based study.初治重型血友病患者抑制剂的发展：一项临床研究和基于登记的研究中纳入患者和结局的比较。
Haemophilia. 2020 Sep;26(5):809-816. doi: 10.1111/hae.14100. Epub 2020 Jul 6.
10
Authors' Reply to Ravi Jandhyala's Comment on "Patient Registries: An Underused Resource for Medicines Evaluation: Operational Proposals for Increasing the Use of Patient Registries in Regulatory Assessments".作者对拉维·詹迪亚拉就《患者登记册：药物评估中未充分利用的资源：关于在监管评估中增加患者登记册使用的操作建议》的评论的回复
Drug Saf. 2019 Dec;42(12):1517-1518. doi: 10.1007/s40264-019-00863-w.